Pages that link to "Q30334543"
Jump to navigation
Jump to search
The following pages link to Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus (Q30334543):
Displaying 50 items.
- Emerging Vaccine Technologies (Q26783764) (← links)
- The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection (Q26864494) (← links)
- Structure-based design of head-only fusion glycoprotein immunogens for respiratory syncytial virus (Q27333522) (← links)
- Structural basis of respiratory syncytial virus neutralization by motavizumab (Q27659146) (← links)
- Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F (Q27664797) (← links)
- Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus (Q27667750) (← links)
- Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers (Q27667876) (← links)
- Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes (Q27668015) (← links)
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody (Q27677570) (← links)
- Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present (Q28080556) (← links)
- RSV fusion: time for a new model (Q28287657) (← links)
- Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment (Q30240274) (← links)
- GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process (Q30375062) (← links)
- Progressive epitope-blocked panning of a phage library for isolation of human RSV antibodies (Q31055398) (← links)
- A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load In Vivo (Q32099239) (← links)
- Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice (Q33782181) (← links)
- Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge (Q33825073) (← links)
- Characterization of an experimental vaccine for bovine respiratory syncytial virus. (Q33899379) (← links)
- Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range (Q34191108) (← links)
- Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis (Q34224973) (← links)
- Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease (Q34330690) (← links)
- Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies (Q34425648) (← links)
- Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease (Q35070176) (← links)
- Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule (Q35488811) (← links)
- Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge (Q35535626) (← links)
- Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells (Q35689697) (← links)
- Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein (Q36169170) (← links)
- Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age (Q36263882) (← links)
- Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells (Q36281893) (← links)
- Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. (Q36348462) (← links)
- Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. (Q36400958) (← links)
- Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection (Q36438987) (← links)
- Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein (Q36823304) (← links)
- Peptide mimics of a conformationally constrained protective epitopes of respiratory syncytial virus fusion protein (Q36872323) (← links)
- Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres (Q37242405) (← links)
- Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development (Q37536191) (← links)
- Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors (Q37593886) (← links)
- Prospects for defined epitope vaccines for respiratory syncytial virus (Q37721415) (← links)
- Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions (Q38362415) (← links)
- The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals (Q38367554) (← links)
- Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. (Q38394731) (← links)
- Recent advances in the development of subunit-based RSV vaccines. (Q38617302) (← links)
- Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection (Q38637248) (← links)
- Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection (Q38750689) (← links)
- Influence of respiratory syncytial virus strain differences on pathogenesis and immunity (Q39289416) (← links)
- Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after co-immunization (Q39453711) (← links)
- Antigenic structure of human respiratory syncytial virus fusion glycoprotein. (Q39579940) (← links)
- Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. (Q39695161) (← links)
- Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein. (Q40046506) (← links)
- Neutralizing epitopes of RSV and palivizumab resistance in Japan (Q40059727) (← links)